SGHT - Sight Sciences, Inc. News

Sight Sciences Announces Updated FDA Indications For TearCare, Effective August 18

Indications for Use state:"The Sight Sciences TearCare System is a thermal-activated gland expre

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in P

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecar

UBS Maintains Buy on Sight Sciences, Raises Price Target to $8

UBS analyst Patrick Wood maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the price t

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

seekingalpha.com

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

marketbeat.com

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported

defenseworld.net

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences (NASDAQ: SGHT) reported second-quarter revenue growth of 20% year over year, supporte

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Conse

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the qu

Sight Sciences Raises FY2026 Sales Guidance from $83.000M-$89.000M to $88.000M-$92.000M vs $86.083M

Sight Sciences (NASDAQ:SGHT) raises FY2026 sales outlook from $83.000 million-$89.000 million to $88

Sight Sciences Q2 EPS $(0.08) Beats $(0.15) Estimate, Sales $23.388M Beat $21.682M Estimate

Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.08) per share which beat the analyst c

Sight Sciences Reports Second Quarter 2026 Financial Results

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Y

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sci

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#

Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares

Sight Sciences Receives FDA 510(k) Clearance For OMNI Ultra Surgical System; Next-Generation Implant

Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commerci

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MI

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

MENLO PARK, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sci

Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $6

Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises

Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $5.15

Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises

seekingalpha.com

Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared R

seekingalpha.com

Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript

Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Sight Sciences (SGHT) give a sense of how its business performed in

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Conse

Earnings Scheduled For May 6, 2026

Sight Sciences Raises FY2026 Sales Guidance from $82.000M-$88.000M to $83.000M-$89.000M vs $84.695M

Sight Sciences (NASDAQ:SGHT) raises FY2026 sales outlook from $82.000 million-$88.000 million to $83

Sight Sciences Q1 EPS $(0.24) Misses $(0.18) Estimate, Sales $19.700M Beat $18.544M Estimate

Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.24) per share which missed the analyst

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidan

MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sci

Sight Sciences to Present at Two Upcoming Investor Conferences

MENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sc

Sight Sciences Announces the Release of its Sustainability Report

MENLO PARK, Calif. , April 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyec

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sc

defenseworld.net

Insider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells $10,615.30 in Stock

Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) EVP Brenton Taylor sold 2,869 shares of the st

Sight Sciences To Present Data On Two Of Its Proprietary Glaucoma And Dry Eye Technologies, OMNI Sur

Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare company focused on d

U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon

Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company fo

Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $6.5

Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and lowers

12 Health Care Stocks Moving In Thursday's Intraday Session

Sight Sciences Q4 Earnings Assessment

Sight Sciences: Q4 Earnings Insights

Sight Sciences Sees FY2026 Sales $82.000M-$88.000M vs $86.117M Est

Sight Sciences (NASDAQ:SGHT) sees FY2026 sales of $82.000 million-$88.000 million vs $86.117 million

Sight Sciences Q4 EPS $(0.08) Beats $(0.20) Estimate, Sales $20.385M Miss $20.403M Estimate

Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.08) per share which beat the analyst c

Earnings Scheduled For March 4, 2026

Uncovering Potential: Sight Sciences's Earnings Preview

5 Analysts Assess Sight Sciences: What You Need To Know

Stifel Maintains Buy on Sight Sciences, Raises Price Target to $8

Stifel analyst Thomas Stephan maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the pr

Sight Sciences Expects Q4 Total Revenue To Be $20.3M-$20.4M And FY25 Revenue To Be $77.3M- $77.4M

Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company fo

Piper Sandler Upgrades Sight Sciences to Overweight, Raises Price Target to $9

Piper Sandler analyst Adam Maeder upgrades Sight Sciences (NASDAQ:SGHT) from Neutral to Overweigh

UBS Maintains Buy on Sight Sciences, Raises Price Target to $12

UBS analyst Danielle Antalffy maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the pr

Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $9.1

Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises

Morgan Stanley Maintains Equal-Weight on Sight Sciences, Raises Price Target to $8

Morgan Stanley analyst Cecilia Furlong maintains Sight Sciences (NASDAQ:SGHT) with a Equal-Weight